As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh carries a market capitalization of 388.22B, placing it among publicly traded companies globally. Its enterprise value stands at 500.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 388.22B |
| Enterprise Value | 500.21B |
As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has 60.10M shares outstanding.
| Shares Outstanding | 60.10M |
These figures are as of June 30, 2026. The price-to-sales ratio is 14.98, and the price-to-book ratio stands at 0.90.
| PS Ratio | 14.98 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | -5.77 |
| P/OCF Ratio | -6.95 |
These figures are as of June 30, 2026. The EV/Sales ratio of 19.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 500.21B versus a market cap of 388.22B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 19.31 |
As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh maintains a current ratio of 0.75, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.75 |
| Quick Ratio | 0.46 |
| Debt / Equity | 20.93 |
| Debt / EBITDA | -1.14 |
Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh posted a negative return on equity (ROE) of -21.57, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.26, reflecting losses generated across the asset base. The company generates approximately 391.08M in revenue per employee across its workforce of 66.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.41 indicates how many times Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -21.57 |
| Return on Assets (ROA) | -12.26 |
| Revenue Per Employee | 391.08M |
| Employee Count | 66.25 |
| Inventory Turnover | 1.41 |
Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh recorded an income tax benefit of -149.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -122.14B and -90.92B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -149.09M |
As of the close on November 17, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh's stock has declined approximately 69.11% over the past 52 weeks. The 50-day moving average sits at 5,284.30, while the 200-day moving average is 7,488.23.
| 52-Week Price Change | -69.11% |
| 50-Day Moving Average | 5,284.30 |
| 200-Day Moving Average | 7,488.23 |
Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh generated 25.91B in revenue and converted that into -90.92B in net income, yielding earnings per share of -2,030.29. EBITDA reached -92.58B, while operating income came in at -92.58B.
| Revenue | 25.91B |
| Gross Profit | -16.34B |
| Operating Income | -92.58B |
| Pretax Income | -122.14B |
| Net Income | -90.92B |
| EBITDA | -92.58B |
| EBIT | -92.58B |
| Earnings Per Share (EPS) | -2,030.29 |
As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh holds 65.95B in cash and equivalents against 105.58B in total debt, resulting in a net debt position of 38.60B. Total book value stands at 432.03B, with working capital of -36.19B providing operational flexibility.
| Cash & Cash Equivalents | 65.95B |
| Total Debt | 105.58B |
| Net Debt | 38.60B |
| Equity (Book Value) | 432.03B |
| Book Value Per Share | 7,188.96 |
| Working Capital | -36.19B |
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh produced -55.82B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -11.50B in capital expenditures, free cash flow totaled -67.31B - equivalent to -1,120.34 per share.
| Operating Cash Flow | -55.82B |
| Capital Expenditures | -11.50B |
| Free Cash Flow | -67.31B |
| FCF Per Share | -1,120.34 |
Over the twelve months ended June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh posted a gross margin of -63.05, reflecting its pricing power and cost economics. The operating margin of -357.34 and net profit margin of -350.90 provide insight into operational efficiency.
| Gross Margin | -63.05 |
| Operating Margin | -357.34 |
| Pretax Margin | -471.41 |
| Profit Margin | -350.90 |
| EBITDA Margin | -357.34 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 13.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh shareholders.
| Shareholder Yield | 13.09 |
| FCF Yield | -17.34 |
As of June 30, 2026, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has an Altman Z-Score of -0.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.64 |
Already premium?